GlobalData’s PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market Report, provides strategic analysis of the global biosimilars industry. It discusses key market trends, regulatory requirements in various markets, recent deals activity and trends, as well as describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as India – providing in-depth analysis of these markets’ regulatory framework, key domestic players and their biosimilar pipelines, and strategic outlook.
Throughout the report, GlobalData’s analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions
The report provides analysis of the key drivers and trends shaping the global biosimilars industry.
The report discusses the biosimilar regulatory landscape of various markets including developed markets of the US and EU, as well as emerging markets such as China and India. Furthermore, it identifies key domestic players in the various markets discussed and provides analysis of their strategy, manufacturing capacity, and clinical pipeline.
The report contains expert insights on the corporate strategies of current and prospective players in the global biosimilars industry.
The report contains a special case study on Teva Pharmaceutical Industries’ biosimilars business, including an in-depth SWOT analysis of the company
About The Report
GlobalData’s PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market report is an essential source of information and analysis on the global biosimilars industry. Using detailed company data, financial analysis, corporate strategy, and market trends analysis, GlobalData provides in-depth analysis of the current and future growth drivers of the biosimilars industry. The report discusses the various regulatory frameworks under which biosimilars are currently reviewed and regulated. Furthermore, it discusses the key factors shaping and driving the biosimilars business, and provides insights on the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of biosimilars.